Skip to main content
. 2021 Dec 3;7(3):e001711. doi: 10.1136/rmdopen-2021-001711

Figure 1.

Figure 1

Study flow chart shows the number of patients eligible for this study and the number of patients who were included per treatment group. IFX, infliximab; RTX, rituximab.